Antiemetic Effect of Tetrahydrocannabinol. Compared With Placebo and Prochlorperazine

Jacob Bell

New Member
Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis


Author(s) Orr LE, McKernan JF, Bloome B
Journal, Volume, Issue Annals of Internal Medicine 1980;140(11):1431-1433
Major outcome(s) no nausea and no vomiting (complete response) in 73% (40/55 courses) in THC group
Indication Cancer chemotherapy; Nausea/vomiting
Medication Delta-9-THC
Route(s) Oral
Dose(s) 4 x 7 mg/m2 every 4 hours
Duration (days) several days
Participants 55 cancer patients
Design Controlled study
Type of publication
Address of author(s) Medical Oncology Section, Southern California Cancer Center, California Hosp. Medical Center, Los Angeles, California, USA


Abstract

Fifty-five patients harboring a variety of neoplasms and previously found to have severe nausea or emesis from antitumor drugs were given antiemetic prophylaxis in a double-blind, randomized, crossover fashion. Tetrahydrocannabinol (THC), prochlorperazine, and placebo were compared. Nausea was absent in 40 of 55 patients receiving THC, eight of 55 patients receiving prochlorperazine, and five of 55 in the placebo group. The antiemetic effect of THC appeared to be more efficacious for cyclophosphamide, fluorouracil, and doxorubicin hydrochloride, and less so for mechlorethamine hydrochloride and the nitrosureas. Tetrahydrocannabinol appears to offer significant control of nausea in most patients and exceeding by far that provided by prochlorperazine.


Source: Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis
 
Back
Top Bottom